Advanced Search

Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 October;53(5) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 October;53(5):536-45

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUETHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

Frequency: Quarterly

ISSN 1824-4785

Online ISSN 1827-1936

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 October;53(5):536-45

UPDATE ON THE DIAGNOSIS AND TREATMENT OF DIFFERENTIATED THYROID CANCER 

    ORIGINAL ARTICLES

The effectiveness of 124I PET/CT in patients with differentiated thyroid cancer

Capoccetti F., Criscuoli B., Rossi G., Ferretti F., Manni C., Brianzoni E.

1 Nuclear Medicine Unit, Oncologic Department, Macerata Hospital, ASUR Marche ZT 9 Macerata, Italy;
2 Medical Physic Unit, Macerata Hospital, ASUR Marche ZT 9 Macerata, Italy

Aim. Several studies consider 124I PET useful in the evaluation of differentiated thyroid cancer (DTC). The aim of this work was to evaluate the usefulness of 124I positron emission tomography (PET)/computed tomography (CT) for: 1) pretherapeutic staging; 2) optimizing the administering activity in case of remnants ablation; 3) individualizing a complex dosimetry case by case especially in plurimetastatic patients.
Methods. A total of 69 patients were studied in our department between September 2007 and June 2008: 17 male and 52 female, aged 17-83 (mean age 46.6) and, with a simplified method, an expectation dose with a distant therapeutic evaluation, in term of efficacy, was calculated. A total body 124I PET/CT and a whole body scan (WBS) were done, respectively, before and after radiometabolic therapy with 131I and then compared in double blind in 67/69. In 2/69 with a follicular pluri-metastatic DTC (both female, aged 65 and 71), an individualized complex dosimetric study was done.
Results. PET/CT and WBS matched in 58/67 patients (86.6%). We obtained a complete ablation of the thyroid remnants in 60/67 patients (90%). The individualized complex dosimetry tells us that the administrable maximum activity is for: patient 1:13320 MBq and patient 2:9250 MBq.
Conclusion. Iodine-124 PET/CT is a powerful diagnostic tool before administration of 131I therapeutic dose. It allows for a precise dosimetry in plurimetastatic patients. After an empiric dose estimation, the successful percentage in term of thyroid’s remnants ablation was very elevated.

language: English


FULL TEXT  REPRINTS

top of page